Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation

Diabetes

Volumn 56, Issue 5, 2007, Pages 1289-1298

  Emamaullee, Juliet A ^a   Stanton, Laura ^a   Schur, Colleen ^a   Shapiro, A M James ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; FOLLOW UP; GLUCOSE TOLERANCE TEST; GRAFT SURVIVAL; IN VIVO STUDY; LIVER TOXICITY; MALE; METABOLIC DISORDER; MOUSE; NEPHROTOXICITY; NONHUMAN; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; APOPTOSIS; BLOOD GLUCOSE; CASPASES; CYSTEINE PROTEINASE INHIBITORS; ENZYME INHIBITORS; FOLLOW-UP STUDIES; GRAFT SURVIVAL; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TRANSPLANTATION, HOMOLOGOUS;

EID: 34248190170     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-1653     Document Type: Article

References (32)

1. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230-238, 2000
2. Shapiro A, Ricordi C, Hering B, Auchincloss H, Lindblad R, Robertson R, Secchi A, Brendel M, Berney T, Brennan D, Cagliero E, Alejandro R, Ryan E, Diercurio B, P PM, Polonsky K, Reems J, Bretzel R, Bertuzzi F, Froud T, Kandaswamy R, Sutherland D, Eisenbarth G, Segal M, Preiksaitis J, Korbutt G, Barton F, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey J: International multicenter trial of islet transplantation with the Edmonton protocol in type 1 diabetes. N Engl J Med 355:12-24, 2006
3. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM: Five-year follow-up after clinical islet transplantation. Diabetes 54:2060-2069, 2005
4. Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, Matsumoto I, Ihm SH, Zhang HJ, Parkey J, Hunter DW, Sutherland DE: Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 293:830-835, 2005
5. Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, Paraskevas S, Eckman PM, Sageshima J, Nakano M, Sawada T, Matsumoto I, Zhang HJ, Sutherland DE, Bluestone JA: Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 4:390-401, 2004
6. Emamaullee JA, Shapiro AM: Interventional strategies to prevent beta-cell apoptosis in islet transplantation. Diabetes 55:1907-1914, 2006
7. Emamaullee JA, Liston P, Korneluk RG, Shapiro AMJ, Elliott J: XIAP overexpression in islet beta-cells enhances engraftment and minimizes hypoxia-reperfusion injury. Am J Transplant 5:1297-1305, 2005
8. Emamaullee JA, Rajotte RV, Liston P, Korneluk RG, Lakey JR, Shapiro AM, Elliott JF: XIAP overexpression in human islets prevents early posttransplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes 54:2541-2548, 2005
9. Hui H, Khoury N, Zhao X, Balkir L, D'Amico E, Bullotta A, Nguyen ED, Gambotto A, Perfetti R: Adenovirus-mediated XIAP gene transfer reverses the negative effects of immunosuppressive drugs on insulin secretion and cell viability of isolated human islets. Diabetes 54:424-433, 2005
10. Iwata A, Harlan JM, Vedder NB, Winn RK: The caspase inhibitor z-VAD is more effective than CD18 adhesion blockade in reducing muscle ischemiareperfusion injury: implication for clinical trials. Blood 100:2077-2080, 2002
11. Iwata A, Nishio K, Winn RK, Chi EY, Henderson WR Jr, Harlan JM: A broad-spectrum caspase inhibitor attenuates allergic airway inflammation in murine asthma model. J Immunol 170:3386-3391, 2003
12. Seery JP, Cattell V, Watt FM: Cutting edge: amelioration of kidney disease in a transgenic mouse model of lupus nephritis by administration of the caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-(beta-o-methyl)- fluoromethylketone. J Immunol 167:2452-2455, 2001
13. Kawasaki M, Kuwano K, Hagimoto N, Matsuba T, Kunitake R, Tanaka T, Maeyama T, Hara N: Protection from lethal apoptosis in lipopolysaccharide- induced acute lung injury in mice by a caspase inhibitor. Am J Pathol 157:597-603, 2000
14. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, Olszewski AJ, Stieg PE, Lee JP, Przedborski S, Friedlander RM: Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288:335-339, 2000
15. Huang JQ, Radinovic S, Rezaiefar P, Black SC: In vivo myocardial infarct size reduction by a caspase inhibitor administered after the onset of ischemia. Eur J Pharmacol 402:139-142, 2000
16. Montolio M, Tellez N, Biarnes M, Soler J, Montanya E: Short-term culture with the caspase inhibitor z-VAD.fmk reduces beta cell apoptosis in transplanted islets and improves the metabolic outcome of the graft. Cell Transplant 14:59-65, 2005
17. Nakano M, Matsumoto I, Sawada T, Ansite J, Oberbroeckling J, Zhang HJ, Kirchhof N, Shearer J, Sutherland DE, Hering BJ: Caspase-3 inhibitor prevents apoptosis of human islets immediately after isolation and improves islet graft function. Pancreas 29:104-109, 2004
18. Wang T, Singh B, Warnock GL, Rajotte RV: Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes 41:114-117, 1992
19. Davalli AM, Ogawa Y, Scaglia L, Wu YJ, Hollister J, Bonner-Weir S, Weir GC: Function, mass, and replication of porcine and rat islets transplanted into diabetic nude mice. Diabetes 44:104-111, 1995
20. Emamaullee JA, Shapiro AM, Rajotte RV, Korbutt G, Elliott JF: Neonatal porcine islets exhibit natural resistance to hypoxia-induced apoptosis. Transplantation 82:945-952, 2006
21. Davalli AM, Ogawa Y, Ricordi C, Scharp DW, Bonner-Weir S, Weir GC: A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice. Transplantation 59:817-820, 1995
22. Weir GC, Bonner-Weir S: Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53 (Suppl. 3):S16-S21, 2004
23. Yin D, Ding JW, Shen J, Ma L, Hara M, Chong AS: Liver ischemia contributes to early islet failure following intraportal transplantation: benefits of liver ischemic-preconditioning. Am J Transplant 6:60-68, 2006
24. Mellgren A, Schnell Landstrom AH, Petersson B, Andersson A: The renal subcapsular site offers better growth conditions for transplanted mouse pancreatic islet cells than the liver or spleen. Diabetologia 29:670-672, 1986
25. Moberg L, Johansson H, Lukinius A, Berne C, Foss A, Kallen R, Ostraat O, Salmela K, Tibell A, Tufveson G, Elgue G, Nilsson Ekdahl K, Korsgren O, Nilsson B: Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 360:2039-2045, 2002
26. Bennet W, Sundberg B, Groth CG, Brendel MD, Brandhorst D, Brandhorst H, Bretzel RG, Elgue G, Larsson R, Nilsson B, Korsgren O: Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes 48: 1907-1914, 1999
27. Ozmen L, Ekdahl KN, Elgue G, Larsson R, Korsgren O, Nilsson B: Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 51:1779-1784, 2002
28. Biarnes M, Montolio M, Nacher V, Raurell M, Soler J, Montanya E: Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 51:66-72, 2002
29. Davalli AM, Scaglia L, Zangen DH, Hollister J, Bonner-Weir S, Weir GC: Vulnerability of islets in the immediate posttransplantation period: dynamic changes in structure and function. Diabetes 45:1161-1167, 1996
30. Weiss RB: Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat Rep 66:427- 438, 1982
31. Carlsson PO, Palm F, Andersson A, Liss P: Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. Diabetes 50:489-495, 2001
32. Carlsson PO, Palm F, Mattsson G: Low revascularization of experimentally transplanted human pancreatic islets. J Clin Endocrinol Metab 87:5418-5423, 2002